Freia Farmaceutici
Financials
Estimates*
EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|
Revenues | <1m | <1m | 1.2m | 1.4m | 1.7m | 2.4m | 2.7m |
% growth | (12 %) | 103 % | 38 % | 23 % | 18 % | 40 % | 14 % |
EBITDA | <1m | <1m | <1m | <1m | <1m | - | - |
% EBITDA margin | 64 % | 26 % | 16 % | 10 % | 11 % | - | - |
Profit | <1m | <1m | <1m | <1m | <1m | - | - |
% profit margin | 13 % | 6 % | 2 % | 3 % | 3 % | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
€150k Valuation: €150k | Seed | ||
* | €3.3m Valuation: €9.4m 11.1x EV/LTM Revenues 42.6x EV/LTM EBITDA | Late VC | |
Total Funding | AUD5.9m |
Related Content
Recent News about Freia Farmaceutici
EditFounded in 2009 but heir to an intense research and development activity since 2004, Freia Farmaceutici has established a world leadership position in developing plant-based therapeutic solutions for human health through its effective drug discovery and development processes, its intellectual property portfolio and regulatory and manufacturing expertise.
Today Freia possesses, among few pharmaceutical companies in the world, an extensive knowledge as research, development, design, formulation of this plant in the agronomic, extraction and human health product manufacturing fields.
Over the years, Freia has pursued a precise strategy in intellectual property management and production, based on an integrated management of all components: proprietary raw materials, patents, trademarks and clinical evidence.
New therapeutic solutions R&D is a fundamental and crucial activity for Freia Farmaceutici, in order to rise to new therapeutic solutions that respond to unmet medical needs.
Freia faces this commitment by combining its skills and experiences with leading academics and research centers. These partnerships are a vehicle for ever new investment opportunities and represent, in addition to a deepening and expansion of Freia’s scientific network, an enhancement of our knowledge.
Thanks to this commitment, multiple therapeutic solutions are in an advanced stage of development and continue to generate a high interest from the world of research, as evidenced by the high number of collaborations, research agreements and Material Transfer Agreements currently in place with universities, institutions Research and Public and Private Health Structures.
Every day, thanks to new investment, collaboration and partnership opportunities, Freia Farmaceutici is able to find new health requests, opening new research horizons and clinical experimentation.